CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  
  Breast cancer is one of the most rapidly evolving fields in oncology nursing. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, oncology nurses must be well informed of these advances and their associated efficacy benefits and related toxicities. This program provides nurses with access to the latest research developments in the systemic treatment of breast cancer and the perspectives of expert oncology nurses and clinical investigators regarding the application of this emerging research information to patient care. Upon completion of this CNE activity, oncology nurses, nurse practitioners and clinical nurse specialists should be able to formulate a more up-to-date and evidence-based approach to the care of patients with breast cancer.
  
  LEARNING OBJECTIVES
  
  
  • Use case-based learning to formulate individualized disease-management strategies for patients with breast cancer.
  • Discuss the benefits and risks associated with evidence-based systemic therapies used in the treatment of breast cancer, including endocrine agents, chemotherapy regimens and biologic treatments.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer.
  • Recall ongoing trials of investigational approaches in breast cancer, and refer patients and obtain consent for study participation.
  ACCREDITATION STATEMENT
  
  Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  
  This educational activity for 1.5 contact hours is provided by Research To Practice during the period of August 2012 through August 2013.
  
  HOW TO USE THIS CNE ACTIVITY
  
  This is an audio CNE program. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.
  
  To receive credit, participants should read the learning objectives and faculty disclosures, listen to the audio MP3s and complete the Post-test and Educational Assessment and Credit Form located at ResearchToPractice.com/ONSBreast2012/CNE. A statement of CNE credit will be issued only upon completion of the Post-test, with a score of 75% or better, and the Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Georgia Litsas, MSN, ANP-BC, AOCNP
  Nurse Practitioner
  Breast Oncology Center
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Genentech BioOncology; Speakers Bureau: Celgene Corporation, Pfizer Inc.
  
  Joyce O’Shaughnessy, MD
  Co-Director, Breast Cancer Research Program
  Baylor-Charles A Sammons Cancer Center
  Texas Oncology, PA
  US Oncology
  Dallas, Texas
  
  Advisory Committee: Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Caris Diagnostics Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, GTx Inc, Johnson & Johnson Pharmaceuticals, Lilly USA LLC, Roche Laboratories Inc, Sanofi; Speakers Bureau: Bristol-Myers Squibb Company, Celgene Corporation, Sanofi.
  
  Hope S Rugo, MD
  Professor of Medicine
  Director, Breast Oncology and Clinical Trials Education
  University of California, San Francisco
  Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.
  
  G Lita Smith, RN, ACNP
  NP Supervisor
  University of Michigan Comprehensive Cancer Center
  Ann Arbor, Michigan
  
  No real or apparent conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Celgene Corporation, Eisai Inc and Genentech BioOncology.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.